WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
May 28, 2020 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals To Resume Trading
May 15, 2020 12:24 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 15, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces that its...
WPD Pharmaceuticals Comments on SEC Order
May 05, 2020 16:01 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, clarifies the...
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
April 30, 2020 08:00 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial
April 29, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
April 24, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
April 23, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
April 21, 2020 07:00 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its...
WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate
April 16, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company announces that its...
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
April 13, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 13, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company reports that the...